Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy
This study evaluated an extended-cycle oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest, assessing its impact on bleeding patterns, safety, patient acceptance, and contraceptive effectiveness.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (49)
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use via openalex
- Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use via openalex
- Effects of Combined Oral Contraceptive Ethinylestradiol (30 μg) and Dienogest (2 mg) on Carbohydrate Metabolism During 1 Year of Conventional or Extended-Cycle Use via openalex
- Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters via openalex
- Extended and Continuous Use of Hormonal Contraceptives to Reduce Menstruation via openalex
- doi:10.1016/j.contraception.2007.01.014 via openalex
- doi:10.1067/mob.2002.122988 via openalex
- doi:10.1016/j.contraception.2006.10.009 via openalex
- W81673947 via openalex
- doi:10.1016/s0002-9378(98)70047-x via openalex
- doi:10.1016/j.ajog.2006.05.012 via openalex
- doi:10.1016/j.contraception.2005.06.068 via openalex
- doi:10.1016/0002-9378(90)90560-t via openalex
- doi:10.1016/s0015-0282(99)00205-8 via openalex
- doi:10.1016/j.contraception.2006.02.006 via openalex
- doi:10.1016/s0010-7824(99)00043-8 via openalex
- doi:10.1136/bmj.b2890 via openalex
- doi:10.1111/j.1526-4610.2007.00650.x via openalex
- doi:10.1016/j.contraception.2006.07.009 via openalex
- doi:10.1016/s0029-7844(96)00488-7 via openalex
- doi:10.1016/j.ajog.2004.02.012 via openalex
- doi:10.2165/00003495-200464210-00006 via openalex
- doi:10.1097/01.aog.0000175144.08035.74 via openalex
- doi:10.1016/j.contraception.2007.02.005 via openalex
- doi:10.1016/s0029-7844(03)00014-0 via openalex
- doi:10.1016/j.contraception.2009.07.003 via openalex
- W4285719527 via openalex
- W6603199455 via openalex
- doi:10.1080/13625180701441121 via openalex
- doi:10.1016/s0029-7844(99)00524-4 via openalex
- doi:10.1016/j.contraception.2005.09.009 via openalex
- doi:10.1016/j.contraception.2007.05.081 via openalex
- doi:10.1016/s0140-6736(05)79442-3 via openalex
- doi:10.1097/aog.0b013e3181842071 via openalex
- doi:10.1016/s0010-7824(03)00141-0 via openalex
- doi:10.1093/humrep/dei377 via openalex
- doi:10.1016/j.contraception.2006.03.022 via openalex
- doi:10.1097/01.aog.0000199950.64545.16 via openalex
- doi:10.1016/j.contraception.2004.07.013 via openalex
- doi:10.1016/j.contraception.2004.02.010 via openalex
- doi:10.1016/j.ajog.2005.12.045 via openalex
- doi:10.1016/j.contraception.2006.05.050 via openalex
- doi:10.1160/th04-11-0759 via openalex
- doi:10.1016/j.contraception.2005.09.010 via openalex
- doi:10.1016/j.whi.2004.08.005 via openalex
- doi:10.1016/j.contraception.2006.07.005 via openalex
- doi:10.1016/j.ajog.2006.02.048 via openalex
- doi:10.1016/j.contraception.2009.05.004 via openalex
- doi:10.1016/0010-7824(96)00137-0 via openalex
Cited by (5)
- Prise en charge des ménorragies : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) 2022
- Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive 2016
- Continuous use of oral contraceptives: an overview of effects and side‐effects 2012
- 10.1016/s1241-8234(23)47284-7 2000
- 10.1016/s1959-5182(22)43849-9 2000
Source provenance
- openalex
- last seen: 2026-05-11T06:39:27.580236+00:00